The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. This issue’s cover story (Page 11) explores exciting treatment advances in pulmonary arterial hypertension (PAH), including the first approval of a therapy indicated for PAH. We address how payers may focus and strategize in this category. 

Other Summer issue highlights:   

• New drugs and strategies to treat PNH, PAH, NASH and MS  
• Upcoming IRA provisions and their impact on your business and members  
• Star Ratings measures and how you can maintain or boost your results  
• Insights to help tackle the obesity epidemic with holistic solutions  
• AI implications for health care 
   

Explore the report